Related coverage linked through entity extraction aliases.
Feb 16, 2026
The drug development services market is projected to reach $31.5 billion in 2026, growing at 12.2% CAGR, while AI-designed drugs enter pivotal Phase III trials that will determine whether the technology can improve clinical success rates beyond the industry's persistent 90% failure rate.
Feb 18, 2026
The global AI in biotechnology market was valued at USD 1,033 million in 2024 and is projected to reach USD 1,971 million by 2031, growing at a CAGR of 10.6%. A separate AI in precision medicine market is forecast to reach $38.88 billion by 2034 with a 35.5% CAGR.
Feb 12, 2026
President Trump signed a spending package funding the National Institutes of Health at nearly $49 billion, the highest level ever, reversing his earlier push for a 40% budget cut to medical research.
Feb 13, 2026
California-based Centivax has begun dosing participants in a Phase 1A clinical trial of Centi-Flu 01, a universal influenza vaccine designed to target conserved viral regions across all flu strains. Initial data from approximately 180 participants is expected within the year.
Feb 13, 2026
Artificial intelligence is increasingly used to analyze Alzheimer's datasets and inform drug discovery, while researchers identify promising new drug targets including the IDOL enzyme and somatostatin receptors that could lead to more affordable treatments.
